Screener
Xeris Biopharma Holdings, Inc. XERS Interest Expense
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The source filing: Xeris Biopharma Holdings, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001867096-26-000065
FAQ
- What is Xeris Biopharma Holdings, Inc.'s interest expense?
- Xeris Biopharma Holdings, Inc. (XERS) reported interest expense of $6.95M in Q2 2026.
- How has Xeris Biopharma Holdings, Inc.'s interest expense changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s interest expense decreased by 5.6% year-over-year, from $7.36M to $6.95M.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s interest expense?
- Over 4 years (2021 to 2025), Xeris Biopharma Holdings, Inc.'s interest expense has grown at a 41.9% compound annual growth rate (CAGR), from $7.18M to $29.08M.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.
Ask your AI about Xeris Biopharma Holdings, Inc.'s interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude